HIV-2 infects resting CD4+ T cells but not monocyte-derived dendritic cells
© Chauveau et al.; licensee BioMed Central. 2015
Received: 18 November 2014
Accepted: 17 December 2014
Published: 13 January 2015
Human Immunodeficiency Virus-type 2 (HIV-2) encodes Vpx that degrades SAMHD1, a cellular restriction factor active in non-dividing cells. HIV-2 replicates in lymphocytes but the susceptibility of monocyte-derived dendritic cells (MDDCs) to in vitro infection remains partly characterized.
Here, we investigated HIV-2 replication in primary CD4+ T lymphocytes, both activated and non-activated, as well as in MDDCs. We focused on the requirement of Vpx for productive HIV-2 infection, using the reference HIV-2 ROD strain, the proviral clone GL-AN, as well as two primary HIV-2 isolates. All HIV-2 strains tested replicated in activated CD4+ T cells. Unstimulated CD4+ T cells were not productively infected by HIV-2, but viral replication was triggered upon lymphocyte activation in a Vpx-dependent manner. In contrast, MDDCs were poorly infected when exposed to HIV-2. HIV-2 particles did not potently fuse with MDDCs and did not lead to efficient viral DNA synthesis, even in the presence of Vpx. Moreover, the HIV-2 strains tested were not efficiently sensed by MDDCs, as evidenced by a lack of MxA induction upon viral exposure. Virion pseudotyping with VSV-G rescued fusion, productive infection and HIV-2 sensing by MDDCs.
Vpx allows the non-productive infection of resting CD4+ T cells, but does not confer HIV-2 with the ability to efficiently infect MDDCs. In these cells, an entry defect prevents viral fusion and reverse transcription independently of SAMHD1. We propose that HIV-2, like HIV-1, does not productively infect MDDCs, possibly to avoid triggering an immune response mediated by these cells.
HIV-1 and HIV-2 share many similarities in their genetic organization, modes of replication and potential interaction with their hosts . However, major differences exist regarding the clinical consequences of infection. In the absence of antiretroviral treatment, progression to immunodeficiency is more rare and occurs more slowly with HIV-2 than with HIV-1 [1,2]. About 10-30% of HIV-2-infected patients are long-term non-progessors or viral controllers [3-5]. Viral RNA levels in HIV-2 infection are about 30 times lower than in HIV-1 infection, and viral DNA levels are also reduced [1,2,6-9]. However, as for HIV-1, disease progression in HIV-2-infected individuals has been associated with increased chronic immune activation, CD4+ T cell depletion and alterations in circulating monocytes and myeloid DCs [1,2,10-13].
Why HIV-2 is less pathogenic than HIV-1, and why HIV-2 provides partial cross-protection against HIV-1 disease progression in dually infected individuals, remains partly understood [1,4,14,15]. It has been proposed that HIV-2 replication may be more efficiently controlled by the immune response. For instance, most of HIV-2-infected individuals produce neutralizing antibodies [2,16]. HIV-2 is more sensitive to neutralization than HIV-1, likely because HIV-2 Env proteins expose multiple cross-reactive epitopes and have fewer glycosylation sites in the V3 loop than HIV-1 [17-19]. In addition to a strong humoral response, HIV-2-infected donors have well-preserved and polyfunctional HIV-specific CD4+ and CD8+ T cell responses that are associated with delayed disease progression [20-22]. The innate immune response may also be very active against HIV-2. It has been reported that in vitro, HIV-1 is more resistant to type-I IFN than HIV-2 and SIVmac . This suggests that some cellular restriction factors, induced by type-I IFN, may be particularly active against HIV-2. For example, HIV-2 is more sensitive to restriction by Trim5α than is HIV-1 . There are strain-specific variations in HIV-2 sensitivity to Trim5α, depending on motifs within the capsid . Lv2 is another example of an unidentified factor that restricts infection of some HIV-2 viruses, but not HIV-1, following virus entry [26,27]. The block manifests after reverse transcription but prior to nuclear entry, and sensitivity to restriction maps to the HIV-2 envelope and capsid genes [26,27]. Tetherin, a cellular protein blocking viral release, is also differently counteracted by HIV-1 and HIV-2. In HIV-1, the anti-tetherin activity is conferred by Vpu, whereas in HIV-2, the intracytoplasmic portion of Env mediates this effect [28,29]. Another protein, the recently identified RNA-associated early-stage anti-viral factor (REAF), inhibits both HIV-1 and HIV-2 just after cell entry .
The restriction factor SAMHD1 blocks HIV replication by degrading intracellular dNTPs and HIV-1 RNA [31-37]. SAMHD1 inhibits reverse transcription in non-diving cells, such as monocytes, macrophages, dendritic cells and non-activated CD4+ lymphocytes [31-36]. In dividing cells such as activated CD4+ T cells, SAMHD1 is phosphorylated and does not restrict HIV-1 [38-40]. HIV-2 and some SIV strains encode the accessory protein Vpx, which degrades SAMHD1 and allows escape from this restriction, whereas HIV-1 lacks a Vpx-like activity. The anti-SAMHD1 activity is conserved in Vpx alleles isolated from viremic or aviremic HIV-2-infected individuals . It has been proposed that HIV-2, through the SAMHD1-degrading action of Vpx, may trigger a more efficient immune response by productively infecting dendritic cells (DCs) . HIV-1, in sparing SAMHD1, may avoid productive infection of DCs and thus limit the resulting protective type-I IFN response mounted by these cells [35,43-45]. In addition to degrading SAMHD1, Vpx may also inhibit the function of IRF-5 . Of note, HIV-1 and HIV-2 differentially interact with other target cells. The kinetics of HIV-1 and HIV-2 replication are different in human primary macrophage cultures . Exposure of plasmacytoid DCs (pDCs) to HIV-1 and HIV-2 differentially mature the cells into IFN-producing cells or Antigen Presenting Cells .
The exact role of Vpx during HIV-2 replication is not fully understood. A comparison between wild-type and Vpx-deleted HIV-2 demonstrated that Vpx is not necessary for viral replication in activated CD4+ T cells and in T cell lines [49-51]. In contrast, HIV-2 infection is poorly supported in resting (non-stimulated) CD4+ T cells. Even in the presence of Vpx, less than 2% of non-stimulated CD4+ T cells are productively infected . Vpx is also required for the productive infection of macrophages by HIV-2 virions pseudotyped with VSV-G . There is controversy regarding the sensitivity of DCs to HIV-2 infection. It has been reported that HIV-2 efficiently replicated in monocyte-derived DCs (MDDCs), using the laboratory-adapted HIV-2 ROD strain, pseudotyped with VSV-G [42,44]. This efficient replication was associated with an immune detection of incoming viral cDNA by the innate sensor cGAS  and with DC maturation. Others reported that neither CCR5-tropic primary HIV-2 isolates nor a CXCR4-tropic laboratory-adapted viral strain could efficiently infect primary myeloid DCs or pDCs, though these viruses could infect primary CD4+ T cells . Moreover, HIV-2 exposure did not promote full maturation of DCs [41,52]. These different results may be due to different experimental systems, DC subsets, or viral strains, and/or to the use of VSV-G-pseudotyped HIV-2 in some studies.
In this study, we explored some virological and immunological aspects of the interaction of HIV-2 with CD4+ T cells and MDDCs. As previously described, HIV-2 spread in primary activated lymphocytes. In resting T cells, productive HIV-2 infection was not detected, but subsequent activation of HIV-2-exposed lymphocytes led to viral replication in a Vpx-dependent manner. In contrast, monocyte-derived DCs (MDDCs) were poorly sensitive to HIV-2 infection, even in the presence of Vpx, and the HIV-2 isolates tested did not trigger a strong type-I IFN response in MDDCs. Therefore, our data do not support the hypothesis that Vpx-mediated SAMHD1 degradation allows HIV-2 productive infection of MDDCs, and thus a potential difference in the ability of HIV-1 and HIV-2 to infect this cell type may not underlie differences in disease pathogenesis.
HIV-2 primary strains replicate in activated CD4+ T cells and infect resting CD4+ T cells
We then asked whether HIV-2 infects resting CD4+ lymphocytes. We purified unstimulated CD4+ T cells from PBMCs, and verified that >95% did not express the activation and proliferation markers CD69 and Ki67 (Additional file 1: Figure S1). These cells were exposed to the HIV-2 isolates ROD, ROK or TOE as well as to HIV-1 (NL4.3) and were cultivated with minimal doses of IL-2 to prevent cell death. As expected , no viral replication was detected in these cells up to 9 days post viral challenge (Figure 1c). Of note, the slight down-regulation of SAMHD1 observed in non-activated CD4 + T cells (in about 10% of the cells) over time (mostly after 7–9 days of culture) may represent dead or dying cells (Figure 1c). However, PHA activation, one day following viral exposure, led to significant HIV-1 and HIV-2 replication. In the case of HIV-2, concomitant and strong SAMHD1 down-regulation was observed in activated cells (Figure 1c). Similar results were obtained when CD4+ T cells were activated 4 days after viral exposure (not shown).
Role of HIV-2 Vpx in primary CD4+ T cells
In resting CD4+ T cells, as observed with the other HIV-2 strains, the GL-AN viruses did not lead to productive infection. However, GL-AN WT, but not GL-AN ∆Vpx, replicated in CD4+ T cells stimulated one day (Figure 2b) or four days (not shown) following viral challenge. This replication was associated with a down-regulation of SAMHD1.
Altogether, these results suggest that upon HIV-2 exposure, unstimulated lymphocytes harbor virus but do not produce viral antigens. This may be due to pre-integration defects and/or a HIV LTR transcription block associated with their quiescent status . Moreover, this non-productive infection requires Vpx, and leads to viral outgrowth after lymphocyte stimulation.
Monocyte-derived dendritic cells are poorly sensitive to HIV-2
VSV-G pseudotyping allows productive HIV-2 infection and viral sensing in MDDCs
The fact that the various HIV-2 strains tested promoted only a partial down-regulation of SAMHD1 suggested that viral entry was impaired in MDDCs. We thus examined the effect of VSV-G pseudotyping on HIV-2 infection by exposing MDDCs to GL-AN (VSV) WT and GL-AN (VSV) ∆Vpx virions. One representative experiment is shown in Figure 3a, and the values obtained with 8 independent donors are shown in Figure 3b,c. Depending on the donor, we observed 10-70% of Gag + cells following exposure to GL-AN (VSV) WT. The Gag signal corresponded to newly synthesized viral proteins, since it was no longer detected in the presence of the reverse transcriptase inhibitor AZT (Figure 3d). This efficient infection was associated with a potent down-regulation of SAMHD1 in up to 90% of the cells. SAMHD1 remained down-regulated in the presence of AZT, indicating that incoming Vpx was responsible for this effect. Moreover, GL-AN (VSV) WT triggered expression of MxA (Figure 3d and Additional file 1: Figure S1b). AZT inhibited MxA production, indicating that viral DNA synthesis was required to mediate sensing of GL-AN (VSV). We then examined the role of Vpx. GL-AN (VSV) ∆Vpx did not productively infect MDDCs nor did it down-regulate SAMHD1 (Figure 3d). Moreover, this virus did not induce MxA in target cells.
Taken together, these results show that VSV-G pseudotyping allows efficient infection of MDDCs by HIV-2. This productive infection leads to sensing of the virus.
VSV-G pseudotyping increases HIV-2 fusion and reverse transcription in MDDCs
Similar results were obtained when using another HIV-2 strain (ROD-GFP) pseudotyped or not with VSV-G. ROD-GFP is derived from ROD9 and carries the GFP gene in place of Nef . We therefore used the GFP signal to quantify productively infected cells. ROD-GFP did not lead to productive infection of MDDCs, whereas VSV-G pseudotyping rescued viral infectivity (Figure 5a). ROD-GFP bound to MDDCs (Figure 5b), but was unable to fuse (Figure 5c) and to promote viral DNA synthesis (Figure 5d).
Altogether, these results indicate that HIV-2 poorly infects MDDCs because of a defect in target cell entry. This defect is overcome by VSV-G pseudotyping, which rescues viral infectivity in these cells.
We studied here HIV-2 replication in primary CD4+ T cells and in MDDCs. We used two primary HIV-2 strains (ROK and TOE), as well as the reference isolate ROD. We focused on the role of Vpx by using the HIV-2 molecular clones GL-AN and ROD-GFP, expressing or not this viral protein.
The HIV-2 isolates replicated in activated CD4+ T cells, as evidenced by the appearance of Gag + cells and by the release of Gag p27 in the supernatants. At each time point, the fraction of Gag + cells was lower than with the HIV-1 strain (NL4.3) tested in parallel. For instance, at day 4 p.i., about 40% of the cells were Gag + with HIV-1, whereas the different HIV-2 strains led to 5 to 25% of infected cells. It is however difficult to formally conclude that HIV-2 spreads less potently than HIV-1 in activated T cells because only one HIV-1 strain was tested here in parallel. Of note, the anti-Gag antibody used in this study (KC57) may recognize HIV-2 antigens less efficiently than those of HIV-1. However, the use of another anti-HIV-2 Gag-specific mAb (25/26A) did not lead to the detection of an increased number of infected cells (not shown). Accordingly, it has been previously reported that in PBMCs infected in vitro, the total amount of viral DNA is lower with HIV-2 ROD than with HIV-1 NL4.3 . We further observed that the mean fluorescence intensity (MFI) of Gag staining was higher with HIV-1 than with HIV-2. This may again reflect a different affinity of the antibody, or may indicate that the number of Gag proteins per infected cell is relatively low with HIV-2.
We characterized the role of Vpx during HIV-2 replication in primary CD4+ T cells. As expected [49-51], both WT and ∆Vpx HIV-2 replicated in PHA-activated lymphocytes, with replication decreasing slightly in the absence of Vpx. Interestingly, all HIV-2 isolates led to a down-regulation of SAMHD1 in infected cells, whereas HIV-1 replicated without degrading this cellular restriction factor. Overall, Vpx was not necessary for HIV-1 or HIV-2 infection in activated CD4+ T cells. This was expected since SAMHD1 is phosphorylated and inactive in cycling cells [38-40]. However, the role of Vpx in the infection of unstimulated primary lymphocytes was dramatic. When exposed to HIV-2, these cells did not become productively infected. PHA stimulation, one or four days following viral exposure, promoted production of HIV-2 ROD, ROK, TOE and GL-AN WT, associated with SAMHD1 down-regulation, whereas GL-AN ∆Vpx did not replicate in this setting. Therefore, Vpx allows HIV-2 infection of resting CD4+ T cells, where SAMHD1 is active. Interestingly, HIV-1 also replicates in CD4+ T cells activated after viral exposure [57,58], without degrading SAMHD1. This may be due to the efficiency of the HIV-1 reverse transcriptase, which displays a low Kd for dNTPs, and may thus function in non-cycling cells with a low dNTP environment [33,34,59,60]. Therefore, both HIV-1 and HIV-2 infect non-cycling CD4+ T cells [31,36], through different mechanisms. HIV-2 may require Vpx to antagonize SAMHD1, in order to increase the intracellular levels of dNTPs or to avoid degradation of viral nucleic acids, probably because the reverse transcription process is less efficient for HIV-2 than for HIV-1 .
Discrepant results have been reported in the literature regarding the interaction of HIV-2 with MDDCs in cell culture systems [42,44,52]. We show here that MDDCs are poorly susceptible to HIV-2 replication, using either the primary viral isolates ROK or TOE, the laboratory-adapted strain ROD, or the molecular clones GL-AN and ROD-GFP. These results confirm and extend those of Duvall et al. , who showed that primary HIV-2 strains, isolated from either viremic and aviremic patients, do not detectably infect myeloid DCs. We also observed that upon exposure with HIV-2, SAMHD1 was partly down-regulated in MDDCs. This suggests that Vpx could access the cytoplasm and that viral fusion could occur to some extent. Future work will help understanding why the partial down-regulation of SAMHD1 was not associated with productive HIV-2 infection. Furthermore, we show here that the GL-AN strain, when pseudotyped with VSV-G, gained the capacity to infect MDDCs. This process required Vpx, since GL-AN (VSV) ∆Vpx did not infect these cells. Therefore, primary HIV-2 isolates do not potently infect MDDCs. That VSV-G rescued infection strongly suggests that an early stage of the viral cycle is restricted in these cells. We further determined that viral binding to MDDCs occurred normally with HIV-2. This is not surprising since HIV binding may involve multiple receptors and molecules (CD4, lectins like DC-SIGN and Siglec/CD169, heparan sulfate, etc.…) and does not necessarily lead to productive infection. However, viral fusion was severely impaired with viruses bearing the HIV-2 envelope. Accordingly, viral DNA synthesis did not occur efficiently. Both viral fusion and DNA synthesis were rescued by VSV-G pseudotyping. It will be worth determining if sensitivity to restriction factors such as LV-2 or REAF [26,30,62] are relieved when viral particles are pseudotyped with VSV-G. Our results also suggest that the productive infection of MDDCs reported in the literature [41,42,44] was due to VSV-G pseudotyping, or to the use of HIV-2 strains with a strong tropism for these cells. It will also be important to determine whether the distinct myeloid DC subsets that have been identified  show different susceptibility to HIV-2 replication.
The low susceptibility of MDDCs to infection by HIV-2 primary isolates was associated with a poor triggering of an innate immune response. In cells exposed to HIV-2, we did not observe induction of the interferon-stimulated gene MxA. Our results confirm those of Duvall et al., who did not observe cell maturation or cytokine production by myeloid DCs exposed to primary HIV-2 isolates or to the CBL-20 laboratory-adapted virus . In addition, we report that infection with VSV-pseudotyped HIV-2 triggered MxA expression in MDDCs. It has been recently reported that the capsids of HIV-2 are determinants for immune detection of viral cDNA in MDDCs by the sensor cGAS . These results were obtained with VSV-G-pseudotyped HIV-2 ROD. Further work will assess how natural HIV-2 isolates can be sensed by cGAS  in MDDCs and other cell types.
Altogether, our results strongly suggest that primary HIV-2 isolates are not efficiently sensed by MDDCs. This does not support the hypothesis that HIV-2, endowed with Vpx, may naturally infect these cells to trigger a protective immune response. We conclude rather that HIV-1 and HIV-2 avoid immune detection in MDDCs through different mechanisms. HIV-1 does not efficiently infect these cells because of a lack of a Vpx-like activity, whereas HIV-2 is restricted at an early entry stage that is not linked to SAMHD1 blockade.
Our findings that MDDCs are not sensitive to HIV-2 infection are in agreement with in vivo observations . It has been reported that in Macaques, myeloid cells were not the site of productive SIV infection, irrespectively of Vpx. Rather, the viral DNA present in myeloid cells of these animals resulted from phagocytosis of infected T cells .
Overall, our results extend previous studies on the interaction of HIV-1 and HIV-2 with CD4+ T cells and DCs. We show that various HIV-2 strains infect activated CD4+ T cells. HIV-2 also latently infects non-stimulated CD4+ T cells. The primary HIV-2 strains tested do not naturally replicate in MDDCs. The main differences between HIV-1 and HIV-2 regarding their interactions with CD4+ T cells and MDDCs include: (i) a potentially lower level of HIV-2 replication in primary activated CD4+ T cells; (ii) a distinct molecular mechanism to target non-activated CD4+ T cells (HIV-2 necessitates Vpx, whereas HIV-1 infection occurs without the need of a Vpx-like activity); (iii) a low efficiency of HIV-2 infection in MDDCs despite the presence of Vpx. It is tempting to speculate that some of these variations may improve our understanding of why the natural course of HIV-2 infection in vivo is different from that of HIV-1 [1,2].
Cells and reagents
PBMCs were isolated from the blood of healthy donors by Ficoll centrifugation. The blood was provided by the EFS (Etablissement français du sang, the Official French blood bank). CD4+ T lymphocytes were isolated from PBMCs by positive selection using magnetic beads (Miltenyi Biotech). When stated, CD4+ T cells were activated by PHA (1 μg mL−1) and grown with IL-2 for 3 days before infection. Primary CD4+ lymphocytes were grown in RPMI medium with 10% heat-inactivated fetal bovine serum (FBS). Monocytes were isolated using a CD14+ selection kit (Miltenyi Biotech). MDDCs were generated by culturing monocytes with 50 ng mL−1 IL-4 and 10 ng mL−1 GM-CSF for 5 days. The reverse transcriptase inhibitor AZT (25 μM) was from the NIH AIDS reagents program.
The ROK primary HIV-2 was isolated nine years after initial diagnosis from an aviremic stage C patient with low CD4 counts (18 and 24 CD4+ T cells/μL at diagnosis and sampling time, respectively). The TOE primary HIV-2 was isolated 3 years after initial diagnosis. During this period, the patient always presented undetectable viral load and a high CD4 cell count (404 to 436 CD4+ T cells/μL at diagnosis and sampling time, respectively). Viruses were isolated by co-cultivation of patient cells with a pool of PHA-activated PBMCs of healthy donors . The primary viruses, as well as the prototype ROD HIV-2 strain isolated from a Cape Verdian patient  were grown either on PHA-stimulated PBMC or in HUT-78 T cells. The pGL-AN WT and ΔVpx plasmids (a kind gift from Florence Margottin-Goguet)  were used to produce viruses by transfection of 293 T cells as described or by amplification on HUT-78 cells. TOE is a X4-tropic virus, whereas ROD and ROK are dual tropic viruses . GL-AN carries a large part of the ROD envelope and likely displays the same receptor usage as ROD. ROD-GFP (a kind gift of Oliver Keppler and Oliver Fackler) is derived from the ROD9 provirus and encodes GFP in Nef . Vesicular Stomatitis Virus type G (VSV-G) pseudotyped viruses GL-AN WT and GL-AN ∆Vpx were generated by cotransfection of 293 T cells with the corresponding proviruses and a VSV-G expression plasmid. The SIV3+ WT and the ∆Vpx plasmids (a kind gift from Monsef Benkirane) were used to produce VLP as described [32,69].
Primary CD4+ T cells were exposed to the indicated virus (15 to 90 ng mL−1 of p27) for 3 h at 37°C in the presence of 2 μg mL−1 of DEAE-Dextran (Sigma-Aldrich). The infection was then monitored by flow cytometry analysis after intracellular Gag staining (KC-57 mAb, Coulter) or by p27 ELISA (Zeptometrix) on the culture supernatants. For infection of non-activated CD4+ T cells, the virus was extensively washed after 4 h at 37°C. Half of the cells were activated with PHA (PHA16, Oxoid, 1 μg mL−1) at day 1 or 4 post infection. The other half was kept in the presence of low concentration of IL-2 (10 U mL−1). The infection was then followed by flow cytometry at the indicated days.
MDDCs were seeded in flat-bottomed 96-well plates at 1×105 cells per well. Cell-free infections in MDDCs were performed using indicated viral doses (50 ng mL−1 of p27 for the VSV-G pseudotyped viruses and 150 to 500 ng mL−1 of p27 for the non-pseudotyped viruses). AZT was added 2 h before infection and kept throughout the infection.
For Gag and SAMHD1 staining, cells were fixed with PFA 4% for 10 min followed by permeabilization with PBS-Triton 0.5% for 20 min. Cells were stained either with the mouse monoclonal antibody (mAb) anti-SAMHD1 (clone I19-18) coupled with Alexa 488  or with a rabbit polyclonal anti-SAMHD1 (Proteintech, 12586-1-AP) for 30 min at 4°C. We previously reported that the levels of SAMHD1 detected by flow cytometry correlated with western blot analysis . Gag stainings were performed with the KC57 mAb (Beckman and Coulter) or with anti-capsid mAb clones 183-H12-5C (NIH AIDS Reagent Program) and 25-26A (Hybridolab, Institut Pasteur). MxA staining was performed with MN143 mAb (provided by Otto Haller) in PBS-Saponine 0.05% for 30 min at 4°C . Samples were analyzed with a FACS CANTO II (Becton Dickinson).
HIV-2 binding assay
HIV-2 GL-AN and ROD-GFP pseudotyped or not with the VSV-G envelope (50 and 150 ng mL−1 of p27) were used to infect 3 × 105 MDDCs in 300 μL at 4°C, in presence of 10 mM Hepes. After 2 h, cells were extensively washed in PBS. Two third of the cells were resuspended in 200 μL PBS + 20 μL Lysis Buffer from the SIV p27 ELISA kit (Zeptometrix). The amount of cell-associated p27 was measured by ELISA.
HIV-2 fusion assay
Viral fusion was assessed as described [54,55]. Briefly, ultracentrifuged HIV-2 virions containing the Blam-Vpr2 fusion protein (a gift of Matthias Dittmar, ) were used to infect 1.5 × 105 MDDCs in 100 μL at 37°C, in presence of 10 mM Hepes and 2 mg.mL-1 DEAE Dextran (Sigma). After 2 hours, cells were washed in cold CO2-independent medium (Invitrogen), without FBS, resuspended in cold CO2-independent medium supplemented with 10% FBS and incubated with the CCF2-AM substrate (CCF2-AM kit, Invitrogen), in the presence of 1.8 mM Probenecid (Sigma), for 2 hours at room temperature. Cells were extensively washed in cold CO2-independent medium and fixed in PBS-PFA 4% for 5 min. The cleaved CCF2-AM fluorescence (excitation at 405 nm, emission at 450 nm) was then immediately measured by flow cytometry using the DAPI channel, on a FacsCanto II (BD).
HIV-2 DNA quantification
Infected cells DNA was extracted using the DNeasy Blood and Tissue kit (Qiagen). 50 ng of total DNA were used with the Platinum qPCR SuperMix-UDG (Life Technologies) and amplified on an Eppendorf Mastercycler ep realplex2 apparatus. HIV-2 Gag primers and probe, as well as PCR conditions have been described .
Statistic analysis was performed with the Mann–Whitney test.
We thank members of the Virus & Immunity Unit for discussions and Alex Compton and Nicoletta Casartelli for critical reading of the manuscript. O.S. was supported by grants from the ANRS, SIDACTION, AREVA Foundation, the Labex IBEID program, the FP7 program HIT Hidden HIV (Health-F3-2012-305762), and Institut Pasteur. This work was supported by the Vaccine Research Institute, Investissements d’Avenir program managed by the ANR-10-LABX-77. We thank Florence Margottin-Goguet, Oliver Keppler, Oliver Fackler, Matthias Dittmar and the NIH AIDS reagents program for the gift of reagents. The authors declare no competing financial interest.
This manuscript is dedicated to the memory of Isabel Puigdomenech.
- Nyamweya S, Hegedus A, Jaye A, Rowland-Jones S, Flanagan KL, Macallan DC. Comparing HIV-1 and HIV-2 infection: lessons for viral immunopathogenesis. Rev Med Virol. 2013;23(4):221–40.PubMedView ArticleGoogle Scholar
- Menendez-Arias L, Alvarez M. Antiretroviral therapy and drug resistance in human immunodeficiency virus type 2 infection. Antivir Res. 2014;102:70–86.PubMedView ArticleGoogle Scholar
- van der Loeff MF, Larke N, Kaye S, Berry N, Ariyoshi K, Alabi A, et al. Undetectable plasma viral load predicts normal survival in HIV-2-infected people in a West African village. Retrovirology. 2010;7:46.PubMed CentralPubMedView ArticleGoogle Scholar
- Esbjornsson J, Mansson F, Kvist A, Isberg PE, Nowroozalizadeh S, Biague AJ, et al. Inhibition of HIV-1 disease progression by contemporaneous HIV-2 infection. N Engl J Med. 2012;367(3):224–32.PubMedView ArticleGoogle Scholar
- Thiebaut R, Matheron S, Taieb A, Brun-Vezinet F, Chene G, Autran B, immunology group of the ACOHIVc. Long-term nonprogressors and elite controllers in the ANRS CO5 HIV-2 cohort. Aids. 2011;25(6):865–7.PubMedView ArticleGoogle Scholar
- MacNeil A, Sarr AD, Sankale JL, Meloni ST, Mboup S, Kanki P. Direct evidence of lower viral replication rates in vivo in human immunodeficiency virus type 2 (HIV-2) infection than in HIV-1 infection. J Virol. 2007;81(10):5325–30.PubMed CentralPubMedView ArticleGoogle Scholar
- Popper SJ, Sarr AD, Travers KU, Gueye-Ndiaye A, Mboup S, Essex ME, et al. Lower human immunodeficiency virus (HIV) type 2 viral load reflects the difference in pathogenicity of HIV-1 and HIV-2. J Infect Dis. 1999;180(4):1116–21.PubMedView ArticleGoogle Scholar
- Gottlieb GS, Hawes SE, Kiviat NB, Sow PS. Differences in proviral DNA load between HIV-1-infected and HIV-2-infected patients. AIDS. 2008;22(11):1379–80.PubMed CentralPubMedView ArticleGoogle Scholar
- Gueudin M, Damond F, Braun J, Taieb A, Lemee V, Plantier JC, et al. Differences in proviral DNA load between HIV-1- and HIV-2-infected patients. AIDS. 2008;22(2):211–5.PubMedView ArticleGoogle Scholar
- Michel P, Balde AT, Roussilhon C, Aribot G, Sarthou JL, Gougeon ML. Reduced immune activation and T cell apoptosis in human immunodeficiency virus type 2 compared with type 1: correlation of T cell apoptosis with beta2 microglobulin concentration and disease evolution. J Infect Dis. 2000;181(1):64–75.PubMedView ArticleGoogle Scholar
- Thiebaut R, Charpentier C, Damond F, Taieb A, Antoine R, Capeau J, et al. Association of soluble CD14 and inflammatory biomarkers with HIV-2 disease progression. Clin Infect Dis. 2012;55(10):1417–25.PubMedView ArticleGoogle Scholar
- Leligdowicz A, Feldmann J, Jaye A, Cotten M, Dong T, McMichael A, et al. Direct relationship between virus load and systemic immune activation in HIV-2 infection. J Infect Dis. 2010;201(1):114–22.PubMedView ArticleGoogle Scholar
- Cavaleiro R, Tendeiro R, Foxall RB, Soares RS, Baptista AP, Gomes P, et al. Monocyte and myeloid dendritic cell activation occurs throughout HIV type 2 infection, an attenuated form of HIV disease. J Infect Dis. 2013;207(11):1730–42.PubMedView ArticleGoogle Scholar
- Kanki PJ, Rowland-Jones S. The protective effect of HIV-2 infection: implications for understanding HIV-1 immunity. AIDS (London, England). 2014;28(7):1065–7.View ArticleGoogle Scholar
- Esbjornsson J, Mansson F, Kvist A, Isberg PE, Nowroozalizadeh S, Biague AJ, et al. Effect of HIV-2 infection on HIV-1 disease progression and mortality. AIDS. 2014;28(4):614–5.PubMedView ArticleGoogle Scholar
- Rodriguez SK, Sarr AD, MacNeil A, Thakore-Meloni S, Gueye-Ndiaye A, Traore I, et al. Comparison of heterologous neutralizing antibody responses of human immunodeficiency virus type 1 (HIV-1)- and HIV-2-infected Senegalese patients: distinct patterns of breadth and magnitude distinguish HIV-1 and HIV-2 infections. J Virol. 2007;81(10):5331–8.PubMed CentralPubMedView ArticleGoogle Scholar
- Shi Y, Brandin E, Vincic E, Jansson M, Blaxhult A, Gyllensten K, et al. Evolution of human immunodeficiency virus type 2 coreceptor usage, autologous neutralization, envelope sequence and glycosylation. J Gen Virol. 2005;86(Pt 12):3385–96.PubMedView ArticleGoogle Scholar
- Kong R, Li H, Georgiev I, Changela A, Bibollet-Ruche F, Decker JM, et al. Epitope mapping of broadly neutralizing HIV-2 human monoclonal antibodies. J Virol. 2012;86(22):12115–28.PubMed CentralPubMedView ArticleGoogle Scholar
- Kong R, Li H, Bibollet-Ruche F, Decker JM, Zheng NN, Gottlieb GS, et al. Broad and potent neutralizing antibody responses elicited in natural HIV-2 infection. J Virol. 2012;86(2):947–60.PubMed CentralPubMedView ArticleGoogle Scholar
- Whittle HC, Ariyoshi K, Rowland-Jones S. HIV-2 and T cell recognition. Curr Opin Immunol. 1998;10(4):382–7.PubMedView ArticleGoogle Scholar
- Duvall MG, Jaye A, Dong T, Brenchley JM, Alabi AS, Jeffries DJ, et al. Maintenance of HIV-specific CD4+ T cell help distinguishes HIV-2 from HIV-1 infection. J Immunol. 2006;176(11):6973–81.PubMedView ArticleGoogle Scholar
- Duvall MG, Precopio ML, Ambrozak DA, Jaye A, McMichael AJ, Whittle HC, et al. Polyfunctional T cell responses are a hallmark of HIV-2 infection. Eur J Immunol. 2008;38(2):350–63.PubMed CentralPubMedView ArticleGoogle Scholar
- Cordeil S, Nguyen XN, Berger G, Durand S, Ainouze M, Cimarelli A. Evidence for a different susceptibility of primate lentiviruses to type I interferons. J Virol. 2013;87(5):2587–96.PubMed CentralPubMedView ArticleGoogle Scholar
- Ylinen LM, Keckesova Z, Wilson SJ, Ranasinghe S, Towers GJ. Differential restriction of human immunodeficiency virus type 2 and simian immunodeficiency virus SIVmac by TRIM5alpha alleles. J Virol. 2005;79(18):11580–7.PubMed CentralPubMedView ArticleGoogle Scholar
- Onyango CO, Leligdowicz A, Yokoyama M, Sato H, Song H, Nakayama EE, et al. HIV-2 capsids distinguish high and low virus load patients in a West African community cohort. Vaccine. 2010;28 Suppl 2:B60–7.PubMedView ArticleGoogle Scholar
- Harrison IP, McKnight A. Cellular entry via an actin and clathrin-dependent route is required for Lv2 restriction of HIV-2. Virology. 2011;415(1):47–55.PubMedView ArticleGoogle Scholar
- Marchant D, Neil SJ, Aubin K, Schmitz C, McKnight A. An envelope-determined, pH-independent endocytic route of viral entry determines the susceptibility of human immunodeficiency virus type 1 (HIV-1) and HIV-2 to Lv2 restriction. J Virol. 2005;79(15):9410–8.PubMed CentralPubMedView ArticleGoogle Scholar
- Neil SJ. The antiviral activities of tetherin. Curr Top Microbiol Immunol. 2013;371:67–104.PubMedGoogle Scholar
- Hotter D, Sauter D, Kirchhoff F. Emerging role of the host restriction factor tetherin in viral immune sensing. J Mol Biol. 2013;425(24):4956–64.PubMedView ArticleGoogle Scholar
- Marno KM, Ogunkolade BW, Pade C, Oliveira NM, O'Sullivan E, McKnight A. Novel restriction factor RNA-associated early-stage anti-viral factor (REAF) inhibits human and simian immunodeficiency viruses. Retrovirology. 2014;11:3.PubMed CentralPubMedView ArticleGoogle Scholar
- Descours B, Cribier A, Chable-Bessia C, Ayinde D, Rice G, Crow Y, et al. SAMHD1 restricts HIV-1 reverse transcription in quiescent CD4(+) T-cells. Retrovirology. 2012;9:87.PubMed CentralPubMedView ArticleGoogle Scholar
- Laguette N, Sobhian B, Casartelli N, Ringeard M, Chable-Bessia C, Segeral E, et al. SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature. 2011;474(7353):654–7.PubMed CentralPubMedView ArticleGoogle Scholar
- Lahouassa H, Daddacha W, Hofmann H, Ayinde D, Logue EC, Dragin L, et al. SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates. Nat Immunol. 2012;13(3):223–8.PubMed CentralPubMedView ArticleGoogle Scholar
- Ayinde D, Casartelli N, Schwartz O. Restricting HIV the SAMHD1 way: through nucleotide starvation. Nat Rev Microbiol. 2012;10(10):675–80.PubMedView ArticleGoogle Scholar
- Puigdomenech I, Casartelli N, Porrot F, Schwartz O. SAMHD1 restricts HIV-1 cell-to-cell transmission and limits immune detection in monocyte-derived dendritic cells. J Virol. 2013;87(5):2846–56.PubMed CentralPubMedView ArticleGoogle Scholar
- Baldauf HM, Pan X, Erikson E, Schmidt S, Daddacha W, Burggraf M, et al. SAMHD1 restricts HIV-1 infection in resting CD4(+) T cells. Nat Med. 2012;18(11):1682–7.PubMedView ArticleGoogle Scholar
- Ryoo J, Choi J, Oh C, Kim S, Seo M, Kim SY, et al. The ribonuclease activity of SAMHD1 is required for HIV-1 restriction. Nat Med. 2014;20(8):936–41.PubMedView ArticleGoogle Scholar
- Cribier A, Descours B, Valadao AL, Laguette N, Benkirane M. Phosphorylation of SAMHD1 by cyclin A2/CDK1 regulates its restriction activity toward HIV-1. Cell reports. 2013;3(4):1036–43.PubMedView ArticleGoogle Scholar
- White TE, Brandariz-Nunez A, Valle-Casuso JC, Amie S, Nguyen LA, Kim B, et al. The retroviral restriction ability of SAMHD1, but not its deoxynucleotide triphosphohydrolase activity, is regulated by phosphorylation. Cell Host Microbe. 2013;13(4):441–51.PubMedView ArticleGoogle Scholar
- Welbourn S, Dutta SM, Semmes OJ, Strebel K. Restriction of virus infection but not catalytic dNTPase activity is regulated by phosphorylation of SAMHD1. J Virol. 2013;87(21):11516–24.PubMed CentralPubMedView ArticleGoogle Scholar
- Yu H, Usmani SM, Borch A, Kramer J, Sturzel CM, Khalid M, et al. The efficiency of Vpx-mediated SAMHD1 antagonism does not correlate with the potency of viral control in HIV-2-infected individuals. Retrovirology. 2013;10:27.PubMed CentralPubMedView ArticleGoogle Scholar
- Lahaye X, Satoh T, Gentili M, Cerboni S, Conrad C, Hurbain I, et al. The capsids of HIV-1 and HIV-2 determine immune detection of the viral cDNA by the innate sensor cGAS in dendritic cells. Immunity. 2013;39(6):1132–42.PubMedView ArticleGoogle Scholar
- Schaller T, Goujon C, Malim MH. AIDS/HIV. HIV interplay with SAMHD1. Science. 2012;335(6074):1313–4.PubMedView ArticleGoogle Scholar
- Manel N, Hogstad B, Wang Y, Levy DE, Unutmaz D, Littman DR. A cryptic sensor for HIV-1 activates antiviral innate immunity in dendritic cells. Nature. 2010;467(7312):214–7.PubMed CentralPubMedView ArticleGoogle Scholar
- Manel N, Littman DR. Hiding in plain sight: how HIV evades innate immune responses. Cell. 2011;147(2):271–4.PubMed CentralPubMedView ArticleGoogle Scholar
- Cheng X, Ratner L. HIV-2 Vpx protein interacts with interferon regulatory factor 5 (IRF5) and inhibits its function. J Biol Chem. 2014;289(13):9146–57.PubMedView ArticleGoogle Scholar
- Marchant D, Neil SJ, McKnight A. Human immunodeficiency virus types 1 and 2 have different replication kinetics in human primary macrophage culture. J Gen Virol. 2006;87(Pt 2):411–8.PubMedView ArticleGoogle Scholar
- Royle CM, Graham DR, Sharma S, Fuchs D, Boasso A. HIV-1 and HIV-2 differentially mature plasmacytoid dendritic cells into IFN-producing cells or APCs. J Immunol. 2014;193(7):3538–48.PubMedView ArticleGoogle Scholar
- Guyader M, Emerman M, Montagnier L, Peden K. VPX mutants of HIV-2 are infectious in established cell lines but display a severe defect in peripheral blood lymphocytes. EMBO J. 1989;8(4):1169–75.PubMed CentralPubMedGoogle Scholar
- Kawamura M, Sakai H, Adachi A. Human immunodeficiency virus Vpx is required for the early phase of replication in peripheral blood mononuclear cells. Microbiol Immunol. 1994;38(11):871–8.PubMedView ArticleGoogle Scholar
- Bergamaschi A, Ayinde D, David A, Le Rouzic E, Morel M, Collin G, et al. The human immunodeficiency virus type 2 Vpx protein usurps the CUL4A-DDB1 DCAF1 ubiquitin ligase to overcome a postentry block in macrophage infection. J Virol. 2009;83(10):4854–60.PubMed CentralPubMedView ArticleGoogle Scholar
- Duvall MG, Lore K, Blaak H, Ambrozak DA, Adams WC, Santos K, et al. Dendritic cells are less susceptible to human immunodeficiency virus type 2 (HIV-2) infection than to HIV-1 infection. J Virol. 2007;81(24):13486–98.PubMed CentralPubMedView ArticleGoogle Scholar
- Haller O, Kochs G. Human MxA protein: an interferon-induced dynamin-like GTPase with broad antiviral activity. J Interferon Cytokine Res. 2011;31(1):79–87.PubMedView ArticleGoogle Scholar
- Cavrois M, De Noronha C, Greene WC. A sensitive and specific enzyme-based assay detecting HIV-1 virion fusion in primary T lymphocytes. Nat Biotechnol. 2002;20(11):1151–4.PubMedView ArticleGoogle Scholar
- Reuter S, Kaumanns P, Buschhorn SB, Dittmar MT. Role of HIV-2 envelope in Lv2-mediated restriction. Virology. 2005;332(1):347–58.PubMedView ArticleGoogle Scholar
- Gueudin M, Braun J, Plantier JC, Simon F. HIV-1 and HIV-2 produce different amounts of 2-long terminal repeat circular DNA in vitro. AIDS. 2008;22(18):2543–5.PubMedView ArticleGoogle Scholar
- Miller MD, Warmerdam MT, Gaston I, Greene WC, Feinberg MB. The human immunodeficiency virus-1 nef gene product: a positive factor for viral infection and replication in primary lymphocytes and macrophages. J Exp Med. 1994;179(1):101–13.PubMedView ArticleGoogle Scholar
- Spina CA, Kwoh TJ, Chowers MY, Guatelli JC, Richman DD. The importance of nef in the induction of human immunodeficiency virus type 1 replication from primary quiescent CD4 lymphocytes. J Exp Med. 1994;179(1):115–23.PubMedView ArticleGoogle Scholar
- Amie SM, Daly MB, Noble E, Schinazi RF, Bambara RA, Kim B. Anti-HIV host factor SAMHD1 regulates viral sensitivity to nucleoside reverse transcriptase inhibitors via modulation of cellular deoxyribonucleoside triphosphate (dNTP) levels. J Biol Chem. 2013;288(28):20683–91.PubMed CentralPubMedView ArticleGoogle Scholar
- Wu L. Cellular and Biochemical Mechanisms of the Retroviral Restriction Factor SAMHD1. ISRN biochemistry 2013 Jul 7. pii: 728392Google Scholar
- Boyer PL, Clark PK, Hughes SH. HIV-1 and HIV-2 reverse transcriptases: different mechanisms of resistance to nucleoside reverse transcriptase inhibitors. J Virol. 2012;86(10):5885–94.PubMed CentralPubMedView ArticleGoogle Scholar
- Neil SJ, Aasa-Chapman MM, Clapham PR, Nibbs RJ, McKnight A, Weiss RA. The promiscuous CC chemokine receptor D6 is a functional coreceptor for primary isolates of human immunodeficiency virus type 1 (HIV-1) and HIV-2 on astrocytes. J Virol. 2005;79(15):9618–24.PubMed CentralPubMedView ArticleGoogle Scholar
- Segura E, Amigorena S. Cross-presentation by human dendritic cell subsets. Immunol Lett. 2013;158(1–2):73–8.PubMedGoogle Scholar
- Gao D, Wu J, Wu YT, Du F, Aroh C, Yan N, et al. Cyclic GMP-AMP synthase is an innate immune sensor of HIV and other retroviruses. Science. 2013;341(6148):903–6.PubMedView ArticleGoogle Scholar
- Calantone N, Wu F, Klase Z, Deleage C, Perkins M, Matsuda K, et al. Tissue myeloid cells in SIV-infected primates acquire viral DNA through phagocytosis of infected T cells. Immunity. 2014;41(3):493–502.PubMedView ArticleGoogle Scholar
- Roquebert B, Damond F, Collin G, Matheron S, Peytavin G, Benard A, et al. HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro. J Antimicrob Chemother. 2008;62(5):914–20.PubMedView ArticleGoogle Scholar
- Clavel F, Guetard D, Brun-Vezinet F, Chamaret S, Rey MA, Santos-Ferreira MO, et al. Isolation of a new human retrovirus from West African patients with AIDS. Science. 1986;233(4761):343–6.PubMedView ArticleGoogle Scholar
- Visseaux B, Hurtado-Nedelec M, Charpentier C, Collin G, Storto A, Matheron S, et al. Molecular determinants of HIV-2 R5-X4 tropism in the V3 loop: development of a new genotypic tool. J Infect Dis. 2012;205(1):111–20.PubMedView ArticleGoogle Scholar
- Goujon C, Jarrosson-Wuilleme L, Bernaud J, Rigal D, Darlix JL, Cimarelli A. With a little help from a friend: increasing HIV transduction of monocyte-derived dendritic cells with virion-like particles of SIV(MAC). Gene Ther. 2006;13(12):991–4.PubMedView ArticleGoogle Scholar
- Lepelley A, Louis S, Sourisseau M, Law HK, Pothlichet J, Schilte C, et al. Innate sensing of HIV-infected cells. PLoS Pathog. 2011;7(2):e1001284.PubMed CentralPubMedView ArticleGoogle Scholar
- Avettand-Fenoel V, Damond F, Gueudin M, Matheron S, Mélard A, Collin G, et al. New sensitive one-step real-time duplex PCR method for group A and B HIV-2 RNA load. J Clin Microbiol. 2014;52(8):3017–22.PubMedView ArticleGoogle Scholar
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.